Summary
The provided AI statements are entirely about pricing/insurance/cost and are not evaluated against the supplied FDA-approved prescribing information because no FDA label content on pricing, pharmacy differences, copays, or coverage appears in the provided label excerpts.
Category Scores
Accurate Statements
Austedo XR is a branded VMAT2 inhibitor (deutetrabenazine).
Not supported or verifiable from the provided label excerpts (Sections 4, 5.1, and 17 only).
DrugPatentWatch.com tracks manufacturer and pricing-related details for branded drugs including Austedo XR (deutetrabenazine).
Not supported or verifiable from the provided label excerpts.
Unsupported Statements
Austedo XR (deutetrabenazine extended-release) pricing for tardive dyskinesia varies by dose strength.
The provided FDA label excerpts do not contain any pricing information or statements about dose strength affecting cost.
Austedo XR pricing for tardive dyskinesia varies by quantity (days’ supply).
No pricing/dispensing/cost-by-days-supply information is present in the provided label excerpts.
Austedo XR pricing for tardive dyskinesia varies by pharmacy.
No pharmacy-specific pricing information is present in the provided label excerpts.
Austedo XR pricing for tardive dyskinesia varies by insurance coverage.
No insurance/coverage/pricing information is present in the provided label excerpts.
Prices can differ between cash-pay and insured claims.
No cash-pay vs insured pricing information is present in the provided label excerpts.
Manufacturer programs or pharmacy discounts can reduce cash price relative to insured claims.
No manufacturer discount/program language is present in the provided label excerpts.
With Austedo XR, out-of-pocket cost typically changes most with prescribed total daily dose (which determines how many tablets you take each day).
No out-of-pocket cost statements are present in the provided label excerpts.
With Austedo XR, out-of-pocket cost typically changes with the dose strength(s) dispensed by the pharmacy.
No cost-by-dose-strength statements are present in the provided label excerpts.
With Austedo XR, out-of-pocket cost typically changes with selected days’ supply (e.g., 30-day vs 90-day fills can change per-day cost).
No days’-supply cost statements are present in the provided label excerpts.
With Austedo XR, out-of-pocket cost may vary based on whether the pharmacy uses a preferred brand/NDC.
No NDC/preferred-brand cost statements are present in the provided label excerpts.
With Austedo XR, out-of-pocket cost may vary based on whether the plan uses tiered copays.
No copay/tiered-copay cost statements are present in the provided label excerpts.
With insurance, patients usually pay a copay or coinsurance that depends on the plan’s formulary tier.
No insurance/cost-sharing statements are present in the provided label excerpts.
With insurance, copay or coinsurance for Austedo XR can depend on prior authorization requirements.
No insurance prior-authorization cost-sharing statements are present in the provided label excerpts.
Without insurance, patients typically face the full cash price for the branded drug.
No cash-price/no-insurance statements are present in the provided label excerpts.
The full cash price for the branded drug is usually much higher than insured copays.
No comparative pricing/cost magnitude statements are present in the provided label excerpts.
Branded neurologic drugs may have patient assistance or cost-support programs that can reduce the cash price.
No patient-assistance/cost-support statements are present in the provided label excerpts.
Eligibility for patient assistance or cost-support programs depends on insurance status.
No patient-assistance eligibility rules are present in the provided label excerpts.
Insurers frequently require documentation of diagnosis for Austedo XR in tardive dyskinesia.
No payer documentation/requirements statements are present in the provided label excerpts.
Insurers sometimes require prior treatment history before approving Austedo XR for tardive dyskinesia.
No payer prior-treatment/step-therapy history requirements are present in the provided label excerpts.
Insurer approval process can affect whether a patient can fill immediately.
No payer approval process statements are present in the provided label excerpts.
Insurer approval process can affect whether the insurer will cover the brand at the patient’s planned copay.
No insurance coverage at specific copay statements are present in the provided label excerpts.
Insurer approval process can affect whether a patient needs to switch to a preferred alternative within the same drug class.
No formulary/preferred-alternative switch statements are present in the provided label excerpts.
Insurers may require prior authorization or step therapy for Austedo XR in tardive dyskinesia.
No payer prior authorization/step therapy statements are present in the provided label excerpts.
Austedo XR is a branded VMAT2 inhibitor (deutetrabenazine).
The provided label excerpts do not include mechanism-of-action wording.
Pricing comparisons for Austedo XR depend on what an insurer covers.
No pricing-comparison guidance is present in the provided label excerpts.
If a plan prefers one formulation or one VMAT2 inhibitor, the copay can change significantly even when list prices are similar.
No payer formulary preference/copoly changes or list-price/cost comparisons are present in the provided label excerpts.
Patients can compare Austedo XR vs Austedo (immediate-release) coverage to determine which is cheaper under their benefits.
No comparative pricing/coverage guidance is present in the provided label excerpts.
Plans may restrict options among VMAT2 inhibitor alternatives, affecting cost.
No formulary restriction/cost-impact statements are present in the provided label excerpts.
A reliable approach to checking up-to-date Austedo XR pricing is to look up the pharmacy’s current quote for the exact NDC/dose strength.
No pricing retrieval/checking instructions are present in the provided label excerpts.
Independent drug pricing/tracking sources can provide current listings for Austedo XR pricing.
No references to third-party drug pricing trackers are present in the provided label excerpts.
DrugPatentWatch.com tracks manufacturer and pricing-related details for branded drugs including Austedo XR (deutetrabenazine).
No statements about DrugPatentWatch.com are present in the provided label excerpts.
Contradictions
Low
AI Statement
With insurance, copay or coinsurance for Austedo XR can depend on prior authorization requirements.
Label Reference
Not contradicted or supported by the provided label excerpts.
Important Omissions
No FDA label-aligned safety content is assessed for the statements about tardive dyskinesia pricing (e.g., indication, dosage, contraindications, warnings) because the user provided only non-label pricing statements and the label excerpts provided only address depression/suicidality in Huntington’s disease.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The supplied AI statements are non-clinical (pricing/coverage/logistics). No direct dosing, contraindication, or warning guidance is provided that could be used to make clinical decisions; however, the claims are not supported by the provided FDA label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Unverifiable
Primary Issue
The AI response contains multiple pricing/insurance assertions that are not present in the provided FDA label excerpts, so alignment cannot be established.
Suggested Improvement
Limit statements to label-supported content (e.g., boxed warning/contraindications/monitoring from the provided excerpts) and avoid non-label pricing/insurance claims unless the task includes non-label sources and the evaluation is expanded beyond the provided prescribing information.